MedPath

Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism

Completed
Conditions
Hyperparathyroidism
Interventions
Other: No intervention are provided
Registration Number
NCT03027349
Lead Sponsor
Azienda USL Modena
Brief Summary

Background:

Primary hyperparathyroidism (PHPT) is often overlooked and underdiagnosed. At present the diagnosis of PHPT remains challenging and is based on serum calcium (Ca) and PTH.

As serum Ca and phosphorous (P) are inversely related in PHPT, the Ca/P ratio might be considered a good candidate tool in the diagnosis of PHPT.

AIM: The aim of this study is to investigate the diagnostic value of the Ca/P ratio in the diagnosis of PHPT.

Study design: Retrospective, observational, cross-sectional, case-control clinical trial will be carried out.

Biochemical measurements will include PTH, Vitamin D, serum Ca, P, albumin, and creatinine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
180
Inclusion Criteria
  • elevated parathormone serum levels
  • normal or elevated calcium serum levels
Exclusion Criteria
  • age younger than 18 years
  • renal and liver failure and insufficiency
  • active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)
  • any type of cancer
  • malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption
  • transplantation
  • sarcoidosis
  • endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism
  • familial hypocalciuric hypercalcemia
  • hypophosphoremia sustained by genetic causes or secondary to other causes.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Control groupNo intervention are providedPatients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges. The exclusion criteria will be: * age younger than 18 years * renal and liver failure and insufficiency * active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc) * any type of cancer * malnutrition, severe obesity (BMI \> 40 kg/m2) and malabsorption * transplantation * sarcoidosis * endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism * familial hypocalciuric hypercalcemia * hypophosphoremia sustained by genetic causes or secondary to other causes.
Study groupNo intervention are providedPatients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia. The exclusion criteria will be: * age younger than 18 years * renal and liver failure and insufficiency * active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc) * any type of cancer * malnutrition, severe obesity (BMI \> 40 kg/m2) and malabsorption * transplantation * sarcoidosis * endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism * familial hypocalciuric hypercalcemia * hypophosphoremia sustained by genetic causes or secondary to other causes.
Primary Outcome Measures
NameTimeMethod
CalciumEnrollment time

Assay performed at the moment of diagnosis

Secondary Outcome Measures
NameTimeMethod
CreatinineEnrollment time

Assay performed at the moment of diagnosis

AlbumineEnrollment time

Assay performed at the moment of diagnosis

ParathormoneEnrollment time

Assay performed at the moment of diagnosis

PhosphorusEnrollment time

Assay performed at the moment of diagnosis

Vitamin DEnrollment time

Assay performed at the moment of diagnosis

Trial Locations

Locations (1)

Azienda USL of Modena

🇮🇹

Modena, Italy

© Copyright 2025. All Rights Reserved by MedPath